REG - Arecor Therapeutics - Arecor to host company and KOL webinar today

Arecor TherapeuticsAnnouncement

21/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240521:nRSU1743Pa&default-theme=true

RNS Number : 1743P  Arecor Therapeutics PLC  21 May 2024

Arecor Therapeutics plc

("Arecor" or the "Group")

 

ARECOR TO HOST COMPANY AND KOL WEBINAR TODAY TO DISCUSS CLINICAL TRIAL RESULTS
FOR ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN AT278 DEMONSTRATING
SUPERIORITY IN PEOPLE WITH TYPE 2 DIABETES

 

·    Company will host a CEO and key opinion leader webinar at 14.30 BST

·    AT278 demonstrates significantly accelerated PK/PD profile compared
to NovoRapid® and Humulin® R U-500 in people with Type 2 Diabetes and high
BMI

·    Confirms previous trial results in people with Type 1 diabetes,
demonstrating AT278 can maintain fast and superior onset of action and glucose
lowering profile irrespective of diabetes type and BMI

·    Enables delivery of a highly concentrated, low volume injection,
offering more effective mealtime glucose control to meet growing unmet need in
patients requiring high daily doses of insulin

·    Creates potential to be the first, and only, ultra-concentrated (500
U/mL) ultra-rapid insulin product enabling miniaturisation of next-generation
insulin pumps

 

Cambridge, UK, 21 May 2024: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier lives,
today announces that it will host a CEO and key opinion leader webinar on the
results of its Phase I clinical trial of that its ultra-concentrated,
ultra-rapid acting insulin candidate, AT278. As announced on 20 May 2024
(https://otp.tools.investis.com/clients/uk/arecor_therapeutics_plc/rns/regulatory-story.aspx?cid=2671&newsid=1821984)
, AT278 et all primary and secondary endpoints, and also demonstrated
superiority to NovoRapid® and Humulin® R U-500, in a Phase I clinical trial
in Type 2 diabetics with a high body mass index (BMI).

 

AT278 (500 U/mL) is an ultra-concentrated, ultra-rapid acting, novel
formulation of insulin that accelerates the absorption of insulin post
injection, even when delivered at a high concentration, and hence a lower
injection volume. With no concentrated (>200 U/mL), rapid acting insulins
on the market, AT278 has potential to be the first, and only, insulin
available to the growing number of patients with high daily insulin
requirements.

 

Speakers at the webinar will be:

 

·    Professor Thomas Pieber, Principal Investigator for the ARE-278-104
clinical trial and Professor of Medicine, Head of the Division of
Endocrinology and Metabolism and Chairman of the Department of Internal
Medicine at Medical University of Graz, Austria

·    Sarah Howell, Chief Executive Officer of Arecor

 

To register to join the live webcast click here
(https://www.lsegissuerservices.com/spark/ARECORTHERAPEUTICS/events/a20a7e23-a0c4-438a-81b2-a0a92369a846)
 and to register for the conference line to ask questions click here
(https://registrations.events/direct/LON6794572) .

 

Please contact ICR Consilium for details on arecor@consilium-comms.com
(mailto:arecor@consilium-comms.com) .

 

-ENDS-

For more information, please contact:

 

 Arecor Therapeutics plc                           www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer          Tel: +44 (0) 1223 426060

                                                   Email: info@arecor.com

 Panmure Gordon (UK) Limited (NOMAD and Broker)    Tel: +44 (0) 20 7886 2500

 Freddy Crossley, Emma Earl (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 WG Partners LLP (Financial Advisor)               Tel: +44 (0)203 705 9321

 Nigel Barnes, Satheesh Nadarajah

 David Wilson, Claes Spang

 ICR Consilium
 Chris Gardner, David Daley, Lindsey Neville       Tel: +44 (0) 20 3709 5700

                                                   Email: arecor@consilium-comms.com

 

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other indications, as well
as working with leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat™ platform is supported by an extensive
patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSEWFMSELSEDI